Heart Failure, Congestive Clinical Trial
— RELAX-AHFOfficial title:
A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
Status | Completed |
Enrollment | 1161 |
Est. completion date | September 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Hospitalized for acute heart failure - Dyspnea at rest or with minimal exertion - Pulmonary congestion - Able to provide informed consent - Systolic blood pressure > 125 mmHg - Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2 Exclusion Criteria: - Use of other IV therapies for acute heart failure - Fever or sepsis - Recent major neurologic event - Recent major surgery - Recent acute coronary syndrome - Other recent investigational drug use |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Israel | Heart Institute | Safed | |
United States | Northwestern University | Chicago | Illinois |
United States | Wayne State University/Detroit Receiving Hospital | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies |
United States, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Relief of dyspnea in acute heart failure | Up to day 5 | No | |
Secondary | Days alive and out of hospital | Up to day 60 | No | |
Secondary | CV death or rehospitalization due to heart failure or renal failure | Up to day 60 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT00383630 -
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
|
Phase 2 | |
Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
Completed |
NCT02772068 -
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
|
Early Phase 1 | |
Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 |